Literature DB >> 14504724

Pharmacokinetics of teicoplanin in critically ill patients undergoing continuous hemodiafiltration.

Kazuaki Yagasaki1, Satoshi Gando, Naoyuki Matsuda, Takashi Kameue, Toshiteru Ishitani, Takeshi Hirano, Ken Iseki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14504724     DOI： 10.1007/s00134-003-1914-9

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  4 in total

1.  Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes.

Authors:  F Thalhammer; A R Rosenkranz; H Burgmann; W Graninger; U Hollenstein; P Schenk; R Thalhammer-Scherrer; O Traindl; W H Hörl; S Breyer
Journal:  Wien Klin Wochenschr       Date:  1997-05-23       Impact factor: 1.704

2.  Evaluation of a novel fluorescence polarization immunoassay for teicoplanin.

Authors:  H Cox; M Whitby; G Nimmo; G Williams
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

3.  Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration.

Authors:  Kazuaki Yagasaki; Satoshi Gando; Naoyuki Matsuda; Takashi Kameue; Toshiteru Ishitani; Takeshi Hirano; Ken Iseki
Journal:  Intensive Care Med       Date:  2003-09-13       Impact factor: 17.440

4.  Teicoplanin pharmacokinetics and dosage recommendations in chronic hemodialysis patients and in patients undergoing continuous veno-venous hemodialysis.

Authors:  K Wolter; M Claus; K Wagner; E Fritschka
Journal:  Clin Nephrol       Date:  1994-12       Impact factor: 0.975
  4 in total
  6 in total

Review 1.  Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors:  Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 2.  A Guide to Understanding Antimicrobial Drug Dosing in Critically Ill Patients on Renal Replacement Therapy.

Authors:  Valentina Pistolesi; Santo Morabito; Francesca Di Mario; Giuseppe Regolisti; Chiara Cantarelli; Enrico Fiaccadori
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  Optimizing Antimicrobial Dosing for Critically Ill Patients with MRSA Infections: A New Paradigm for Improving Efficacy during Continuous Renal Replacement Therapy.

Authors:  Jiaojiao Chen; Sihan Li; Quanfang Wang; Chuhui Wang; Yulan Qiu; Luting Yang; Ruiying Han; Qian Du; Lei Chen; Yalin Dong; Taotao Wang
Journal:  Pharmaceutics       Date:  2022-04-11       Impact factor: 6.525

4.  Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Yuki Hanai; Yoshiko Takahashi; Takashi Niwa; Toshihiko Mayumi; Yukihiro Hamada; Toshimi Kimura; Kazuaki Matsumoto; Satoshi Fujii; Yoshio Takesue
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790

Review 5.  Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy.

Authors:  Lu Li; Xin Li; Yanzhe Xia; Yanqi Chu; Haili Zhong; Jia Li; Pei Liang; Yishan Bu; Rui Zhao; Yun Liao; Ping Yang; Xiaoyang Lu; Saiping Jiang
Journal:  Front Pharmacol       Date:  2020-05-29       Impact factor: 5.810

6.  Teicoplanin inhibits Ebola pseudovirus infection in cell culture.

Authors:  Yizhuo Wang; Rui Cui; Guiming Li; Qianqian Gao; Shilin Yuan; Ralf Altmeyer; Gang Zou
Journal:  Antiviral Res       Date:  2015-11-14       Impact factor: 5.970
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.